Related Experiment Video
Updated: Jan 30, 2026

13:04
Overexpressing Long Noncoding RNAs Using Gene-activating CRISPR
Published on: March 1, 2019
9.3K
[Small Noncoding 4.5SH and 4.5SI RNAs and Their Binding to Proteins]
K A Tatosyan1, A P Koval1, D A Kramerov1,2
1Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russia.
Molekuliarnaia Biologiia
|January 12, 2019
Summary
The functions of small noncoding RNAs 4.5SI and 4.5SH in rodents remain elusive. Research suggests protein X may stabilize 4.5SI RNA, impacting its half-life.
Area of Science:
- Molecular Biology
- RNA Biology
- Genetics
Background:
- Small noncoding RNAs, specifically 4.5SI and 4.5SH, are synthesized by RNA polymerase III and widely expressed in rodent tissues.
- The precise biological functions of these RNAs are not well understood.
Purpose of the Study:
- To investigate the protein interactions and functional roles of 4.5SI and 4.5SH RNAs in murine-like rodents.
- To elucidate the structural basis for protein binding and RNA stability.
Main Methods:
- Crosslinking assays were employed to identify proteins binding to 4.5SI and 4.5SH RNAs.
- Immunoprecipitation was used to confirm the association of these RNAs with the La protein.
- RNA sequence modifications were performed to assess their impact on protein binding and RNA structure.
Main Results:
- Approximately 50% of 4.5SI and 4.5SH RNA molecules were found to be bound by proteins provisionally named X and Y, respectively.
- Both RNAs were associated with the La protein, although it did not crosslink to them.
- The duplex stem at the termini of 4.5SI RNA contributes to its stability compared to 4.5SH RNA.
- Modifying the 5'-end sequence of 4.5SI RNA disrupted protein binding, but restoring the complementary 3'-end sequence re-established both stem structure and binding to protein X.
Conclusions:
- Protein X is presumed to play a role in enhancing the half-life of 4.5SI RNA.
- The structural integrity of 4.5SI RNA, particularly its terminal stem, is crucial for its interaction with protein X and likely influences its stability.
Related Concept Videos
siRNA - Small Interfering RNAs
18.6K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
18.6K
piRNA - Piwi-interacting RNAs
7.6K
PIWI-interacting RNAs, or piRNAs, are the most abundant short non-coding RNAs. More than 20,000 genes have been found in humans that code for piRNAs while only 2000 genes have been found for miRNAs. piRNAs can act at the transcriptional and post-transcriptional levels and have a vital role in silencing transposable elements present in germ cells. They are also involved in epigenetic silencing and activation. Previously, they were thought to function only in germ cells but new evidence suggests...
7.6K
lncRNA - Long Non-coding RNAs
9.9K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.9K
Factors Affecting Protein-Drug Binding: Protein-Related Factors
556
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
556
The Equilibrium Binding Constant and Binding Strength
15.0K
The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
15.0K
Drug Distribution: Plasma Protein Binding
8.8K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
8.8K

